Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 411 • 2017 ACR/ARHP Annual Meeting
Factors That Drive Treatment Recommendation during Rheumatoid Arthritis Patient´s Follow-up, Differ According to Physician Experience
César Sifuentes-Cantú¹, Irazu Contreras-Yañez², Lina Saldarriaga Rivera³, Ana Cecilia Lozada⁴, Marwin Gutierrez⁵ and Virginia Pascual-Ramos¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ³Instituto Nacional de Rehabilitación, Mexico, Mexico, ⁴Division of musculoskeletal and rheumatic diseases, Instituto Nacional de Rehabilitación, Mexico City, Mexico, ⁵Rheumatology, Instituto Nacional de Rehabilitación, Mexico City, Mexico
Background/Purpose: The management plan for rheumatoid arthritis (RA) might be a relatively simple task if only disease activity is considered but might become more complex…
Abstract Number: 848 • 2017 ACR/ARHP Annual Meeting
“Suddenly You Are a Person at Risk of Developing Rheumatoid Arthritis!” Different Perspectives of Individuals on Predictive Testing – Results of an International Qualitative Interview Study
Erika Mosor¹, Michaela Stoffer², Günter Steiner³, Karim Raza⁴, Rebecca J Stack⁴, Gwenda Simons⁴, Marie Falahee⁴, Georg Schett⁵, Matthias Englbrecht⁶, Josef S. Smolen², Axel J. Hueber⁶ and Tanja Stamm⁷, ¹Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria, 1090 Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ³Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Rheumatology, University of Birmingham and Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK, Birmingham, United Kingdom, ⁵Rheumatology and Immunology, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁶Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁷Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Vienna, Austria
Background/Purpose: People at risk of developing rheumatoid arthritis (RA) may be candidates for interventions aimed at preventing RA development [1]. The identification of such at…
Abstract Number: 2008 • 2017 ACR/ARHP Annual Meeting
“Intrathoracic Manifestations of Connective Tissue Diseases on High Resolution Computed Tomography”
Diego Baenas¹, Maira Orozco², María Eugenia Olmos³, Luis Lasca⁴, Paula Riba⁵, Patricio Muszinsky⁵, Juan Pablo Pirola⁶, Verónica Saurit⁷, Alejandro Alvarellos⁷, Ana C. Alvarez⁸, Soledad Retamozo^9,10, Nadia Riscanevo^7,11, Janet Flores¹², Ariel Blua³, Ana María López¹³, Gustavo Muiño¹⁴, Santiago Orozco¹⁵ and Francisco Caeiro¹⁶, ¹Rheumatology Unit, Hospital Privado Universitario de Córdoba, Postgraduate Career of Rheumatology Catholic University of Córdoba., Cordoba, Argentina, ²Radiology, Radiology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ³Pulmonary, Pulmonary Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁴Radiology Unit, Oulton Institute, Cordoba, Argentina, ⁵Radiology, Radiology Unit, Oulton Institute, Cordoba, Argentina, ⁶Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ⁷Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁸Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ⁹Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ¹⁰Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ¹¹Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ¹²Rheumatology Unit, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ¹³Pulmonary Unit, Pulmonary Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ¹⁴Radiology, Radiology Unit,Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ¹⁵Radiology, Radiology Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, ¹⁶Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina
Background/Purpose: Connective tissue diseases (CTD) can cause intrathoracic involvement, increasing patients morbidity and mortality. High-resolution computed tomography (HRCT) is a key method for evaluation of…
Abstract Number: 2795 • 2017 ACR/ARHP Annual Meeting
Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re‑Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and Immunogenicity Results from a Multicenter, Randomized, Double-Blind Study
Hans-Peter Tony¹, Hendrik Schulze-Koops², Klaus Krüger³, Stanley B Cohen⁴, Alan J. Kivitz⁵, Slawomir Jeka⁶, Edit Vereckei⁷, Liyi Cen⁸ and Dmitrij Kollins⁸, ¹Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ³Praxiszentrum St. Bonifatius München, München, Germany, ⁴Metroplex Clinical Research Centre, Dallas, TX, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶2nd University Hospital, CM UMK, Department of Rheumatology and Connective Tissue Diseases,, Bydgoszcz, Poland, ⁷National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁸Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany
Background/Purpose: GP2013, is a biosimilar to European Union (EU) approved reference rituximab (RTX), developed in a stepwise approach that adheres to stringent biosimilar development guidelines.…
Abstract Number: 424 • 2017 ACR/ARHP Annual Meeting
Re-Establishment of Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in Rheumatoid Arthritis Patients after Temporary Discontinuation
Jeffrey Kaine¹, John Tesser², Ryan DeMasi³, Liza Takiya³, Lisy Wang⁴, Mark Snyder³, Haiyun Fan⁴ and Jürgen Wollenhaupt⁵, ¹Sarasota Arthritis Research Center, Sarasota, FL, ²Arizona Arthritis & Rheumatology Associates, Glendale, AZ, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assessed tofacitinib efficacy and safety after temporary discontinuation and…
Abstract Number: 902 • 2017 ACR/ARHP Annual Meeting
Evidence for Inhibition of Osteoclastogenesis By Cytomegalovirus Infection: Implication in RA Bone Erosion and Identification of a Cellular Protein As a Therapeutic Target
Benjamin Rauwel¹, Michel Baron¹, Adeline Ruyssen-Witrand², Delphine Nigon³, Yannick Degboé², Jacques Izopet¹, Alain Cantagrel¹ and Jean-Luc Davignon¹, ¹CPTP, INSERM UMR 1043, Toulouse, France, ²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ³Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France
Background/Purpose: Exacerbated differentiation of monocytes into osteoclasts (OC) contributes to the pathogenesis of rheumatoid arthritis (RA) resulting in severe bone erosion and functional damage. Osteoclastogenesis…
Abstract Number: 2013 • 2017 ACR/ARHP Annual Meeting
Physician Experience and Patient´s Disease Activity Affect the Impact of Musculoskeletal Ultrasound on the Treatment Decision in Rheumatoid Arthritis Patients
César Sifuentes-Cantú¹, Irazu Contreras-Yañez², Marwin Gutierrez³ and Virginia Pascual-Ramos⁴, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ³Rheumatology, Instituto Nacional de Rehabilitación, Mexico City, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: In a real clinical setting of RA outpatients, we previously showed that musculoskeletal ultrasound (MUS) added to clinical evaluation impacted the treatment decision in…
Abstract Number: 2796 • 2017 ACR/ARHP Annual Meeting
A Randomized, Double Blind Trial over 52 Weeks to Demonstrate Bioequivalence of GP2013 and Reference Rituximab in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Stanley B Cohen², Morton Scheinberg³, Tamas Shisha⁴, Dmitrij Kollins⁴, Peijuan Zhu⁵, Liyi Cen⁴, Alan J. Kivitz⁶, Andra Rodica Balanescu⁷, Juan J. Gomez-Reino⁸ and Hans-Peter Tony⁹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Metroplex Clinical Research Centre, Dallas, TX, ³Rheumatology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, ⁴Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany, ⁵Clinical Pharmacology, Sandoz, a Novartis Division, NJ, NJ, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Research Center of Rheumatic Diseases, “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, ⁸BIOBADASER, Santiago, Spain, Santiago de Compostela, Spain, ⁹Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Rituximab (RTX) is a mAB indicated for the treatment of RA in patients with inadequate response to anti-TNF therapy. The current study compares the…
Abstract Number: 428 • 2017 ACR/ARHP Annual Meeting
Impact of Smoking Cessstion Advise in Patients with Rheumatoid Arthritis to Help Quit Smoking
Shama Khan¹, Ahmad Butt¹, Emmett Brennan², Ausaf Mohammad¹ and Killian O Rourke³, ¹Rheumatology, Midlands Regional Hospital, Tullamore, Ireland, ²Tullamore, Midlands Regional Hospital, Tullamore, Ireland, ³Rheumatology, Midlands Regional Hospital, Tullamore, Co Offaly, Ireland
Background/Purpose: Smoking is associated with an increased risk of comorbidities in rheumatoid arthritis (RA) and may reduce the efficacy of anti-rheumatic therapies. Smoking cessation is…
Abstract Number: 1055 • 2017 ACR/ARHP Annual Meeting
A Combination of Self-Reported Symptoms and ACPA Testing Can Identify Individuals with Previously Undiagnosed Inflammatory Arthritis in a Health-Fair Setting
Elizabeth A. Bemis¹, Nicholas Ellinwood², Kaylynn Aiona³, Christopher C. Striebich⁴ and Kevin D. Deane⁵, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Pharmacology and Toxicology Graduate Group, University of California Davis, Davis, CA, ³Denver Health and Hospitals and Colorado School of Public Health, Denver, CO, ⁴Division of Rhuematology, University of Colorado School of Medicine, Aurora, CO, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Early identification and treatment of inflammatory arthritis (IA) and in particular rheumatoid arthritis (RA) can lead to improved outcomes. However, there are often delays…
Abstract Number: 2239 • 2017 ACR/ARHP Annual Meeting
The Recall Program: Data from a Multicenter Educational Event on Patients with Rheumatoid Arthritis
Andrea Delle Sedie¹, Emilio Filippucci², Oscar Epis³, Pierluigi Macchioni⁴, Sebastiano Tropea⁵, Carlo Bonali⁶, Marco Canzoni⁷ and Annamaria Iagnocco⁸, ¹Department Rheumatology, University of Pisa, Pisa, Italy, ²Rheumatology Unit, Università Politecnica delle Marche, Jesi, Italy, ³Rheumatology Unit, Ospedale Niguarda, Milano, Italy, ⁴Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, ⁵ASP7, Busacca Hospital, Ragusa, Italy, ⁶Rheumatology Unit,, Ospedale San Paolo, Bari, Italy, ⁷Local Health Unit (ASL) Rome 1, Rome, Italy, ⁸Academic Rheumatology Unit, Università degli Studi di Torino, Torino, Italy
Background/Purpose: ultrasound (US) is able to show subclinical synovitis in patients (pts) with rheumatoid arthritis (RA) who are in clinical remission (CR); this has been…
Abstract Number: 2827 • 2017 ACR/ARHP Annual Meeting
A Novel Statistical Method to Resolve Cellular Heterogeneity in Disease Tissues: Integrating Transcriptomic Data in Accelerating Medicines Partnership (AMP) – RA Network Phase 1 Data
Fan Zhang¹, Kamil Slowikowski², Chamith Fonseka¹, Kevin Wei³, Maria Gutierrez-Arcelus⁴, James Lederer⁵, Nir Hacohen⁶, Vivian P. Bykerk⁷, Michael Holers⁸, Peter Gregersen⁹, Mandy J. McGeachy¹⁰, Larry W. Moreland¹¹, Andrew Filer¹², Costantino Pitzalis¹³, Yvonne C. Lee¹⁴, Jennifer H. Anolik¹⁵, Michael Brenner⁴ and Soumya Raychaudhuri¹⁶, ¹Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Harvard Medical School, Boston, MA, ⁷2-005, Mt Sinai Hospital, Toronto, ON, Canada, ⁸Medicine, Division of Rheumatology, University of Colorado Denver, Aurora, CO, ⁹The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ¹⁰Medicine, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ¹³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ¹⁴Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ¹⁶Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Detecting distinct cellular subsets in disease tissues is key to understanding the pathogenesis of immune diseases, for example in synovial tissues in rheumatoid arthritis…
Abstract Number: 430 • 2017 ACR/ARHP Annual Meeting
Implementation of a Treat-to-Target Remission Strategy for Rheumatoid Arthritis in Australian Public and Private Rheumatology Clinics – Identification of Clinician and Patient Barriers
Helen Benham¹, Hedva Chiu², Joanne Tesiram³, Peter Landsberg⁴, Andrew A. Harrison⁵, Peter Nash⁶, Ranjeny Thomas⁷ and Mieke van Driel⁸, ¹The University of Queensland Faculty of Medicine, Brisbane, Australia, ²The University of Queensland Faculty of Medicine, Woolloongabba, Australia, ³Rheumatology, Princess Alexandra Hospital, Woolloongabba, Australia, ⁴Princess Alexandra Hospital, Woolloongabba, Australia, ⁵Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ⁶University of Queensland, Brisbane, Australia, ⁷Diamantina Institute, Diamantina Institute University of Queensland, Brisbane, Australia, ⁸Primary Care Clinical Unit, The University of Queensland Faculty of Medicine, Herston, Australia
Background/Purpose: Treat-to-target in rheumatoid arthritis (RA-T2T) improves outcomes for people living with RA. Implementing T2T in routine clinical practice however presents many challenges and an…
Abstract Number: 1087 • 2017 ACR/ARHP Annual Meeting
Rheumatology Clinic Smoking Cessation Protocol Markedly Increases Quit Line Referrals
Christie M. Bartels¹, Edmond Ramly², Daniel Panyard³, Diane Lauver⁴, Heather Johnson⁵, Zhanhai Li⁶, Emmanuel Sampene⁷, Megan Piper⁸ and Patrick McBride⁵, ¹Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI, ²Industrial and Systems Engineering, University of Wisconsin College of Engineering, Madison, WI, ³Population Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin-Madison School of Nursing, Madison, WI, ⁵Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁸University of Wisconsin Center for Tobacco Research and Intervention, Madison, WI
Background/Purpose: Smoking predicts higher incidence, greater severity, and reduced treatment responses in rheumatoid arthritis, lupus, and spondyloarthritis. However, cessation advice and quit line referral occur…
Abstract Number: 2261 • 2017 ACR/ARHP Annual Meeting
Supporting Smoking Cessation in RA and SLE: Identifying Patient-Centered Outcomes
Aimée Wattiaux¹, Laura Block², Andrea Gilmore-Bykovskyi², Edmond Ramly³, Jane Sadusky⁴, Megan Piper⁵, Brittany Bettendorf⁶, Ann Rosenthal⁷ and Christie M. Bartels⁸, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin School of Nursing, Madison, WI, ³Industrial and Systems Engineering, University of Wisconsin College of Engineering, Madison, WI, ⁴Research Consultant, Madison, WI, ⁵University of Wisconsin Center for Tobacco Research and Intervention, Madison, WI, ⁶Rheumatology, Medical College of Wisconsin, MIlwaukee, WI, ⁷Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁸Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI
Background/Purpose: Patients with RA and SLE are at higher risk for premature cardiovascular disease (CVD) than peers. Smoking is a leading modifiable risk factor for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].